

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**Current Report  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 14, 2018**

---

**Seattle Genetics, Inc.**

(Exact name of Registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**0-32405**  
(Commission  
File Number)

**91-1874389**  
(I.R.S. Employer  
Identification No.)

**21823 30th Drive SE**  
**Bothell, Washington 98021**  
(Address of principal executive offices, including zip code)

**(425) 527-4000**  
(Registrant's telephone number, including area code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On March 14, 2018, the Board of Directors (the “Board”) of Seattle Genetics, Inc. (the “Company”) elected Alpna Seth, Ph.D. to the Board as a Class I director for a term expiring at the 2020 annual meeting of the Company’s stockholders, effective March 15, 2018. There is no arrangement or understanding with any person pursuant to which Dr. Seth was appointed as a member of the Board.

In accordance with the Company’s compensation policy with respect to annual cash fees for non-employee directors, Dr. Seth will receive an annual cash retainer of \$50,000 for her service on the Board, which will be prorated during 2018. In addition, effective as of March 15, 2018 (the “Grant Date”), the Board granted Dr. Seth a nonstatutory stock option to purchase 14,250 shares of Company’s common stock (the “Option”) and a restricted stock unit award covering 5,750 shares of the Company’s common stock (the “RSU Award”) pursuant to the terms of the Company’s Amended and Restated 2007 Equity Incentive Plan. One quarter of the shares underlying the Option will vest on the first anniversary of the Grant Date and 1/36<sup>th</sup> of the remaining shares shall vest each month thereafter. The RSU Award will vest in its entirety on the third anniversary of the Grant Date. The Company also intends to enter into its standard form of indemnification agreement with Dr. Seth (the “Indemnification Agreement”), which will require the Company, under the circumstances and to the extent provided for therein, to indemnify Dr. Seth to the fullest extent permitted by law against certain expenses and other amounts incurred by Dr. Seth as a result of being made a party or threatened to be made a party to certain actions, suits or proceedings by reason of her position as a director (or employee or other agent) of the Company. The foregoing is only a brief description of the Indemnification Agreement, does not purport to be complete, and is qualified in its entirety by reference to the form of Indemnification Agreement previously filed by the Company as Exhibit 10.29 to the Company’s Registration Statement on Form S-1/A (File No. 333-50266), filed with the Securities and Exchange Commission on January 4, 2001.

A copy of the press release announcing Dr. Seth’s appointment to the Board is filed as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits

99.1 [Press Release of Seattle Genetics, Inc. dated March 15, 2018.](#)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SEATTLE GENETICS, INC.**

Date: March 14, 2018

By: /s/ Clay B. Siegall

Clay B. Siegall

President and Chief Executive Officer

FOR RELEASE: **Thursday, March 15, 2018**  
**5:00 a.m. Pacific Time**



### **Seattle Genetics Appoints Dr. Alpa Seth to Board of Directors**

Bothell, WA – March 15, 2018 — Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Alpa Seth, Ph.D. has been appointed to the company’s Board of Directors. Dr. Seth has more than 20 years of global experience in the healthcare and biotechnology/pharmaceutical industry, including senior leadership positions at Biogen. She currently serves as Chief Operating Officer of Vir Biotechnology, a San Francisco-based biotechnology company focused on transforming the care of people with serious infectious diseases.

“Alpa’s diverse experience and track record of success in business and drug development, global operations and product launches, coupled with strong scientific depth and leadership skills, make her an ideal addition to our Board of Directors,” said Clay Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. “I look forward to her contributions as we continue to deliver on Seattle Genetics’ strategic priorities, including commercializing and growing ADCETRIS® (brentuximab vedotin) and advancing our late-stage oncology pipeline, including enfortumab vedotin, tisotumab vedotin and tucatinib.

Dr. Seth commented, “Seattle Genetics is on the cusp of a significant inflection point in its transition into a global, multi-product oncology company. In parallel with the great progress expanding the ADCETRIS franchise for CD30-expressing hematologic malignances, the team has assembled an impressive pipeline of late-stage clinical programs for solid tumors. I look forward to working with the rest of the Board and with members of the senior management team to drive progress and shareholder value.”

Alpa Seth, Ph.D. currently serves as the Chief Operating Officer of Vir Biotechnology, Inc. Prior to joining Vir in July 2017, Dr. Seth was Senior Vice President and Global Head of the Biosimilars business for Biogen, Inc. headquartered in Zug, Switzerland since 2014. From 1998 through 2014, she held a range of leadership roles at Biogen in market and business development, drug development and commercial, including founding Managing Director of Biogen Idec India and Program Executive for several of Biogen’s major cross-functional drug development programs and product launches. She holds a Ph.D. in Biochemistry and Molecular Biology from University of Massachusetts Medical School and conducted her post-doctoral research at Harvard University in Immunology and Structural Biology, both as a Howard Hughes Medical Institute Fellow. She is also a 2002 graduate of the Advanced Management Program at Harvard Business School.

#### **About Seattle Genetics**

Seattle Genetics is an innovative biotechnology company dedicated to improving the lives of people with cancer through novel targeted therapies. The company’s industry-leading ADC technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Seattle Genetics commercializes ADCETRIS® (brentuximab vedotin) for the treatment of several types of CD30-

---

expressing lymphomas. The company is also advancing a robust pipeline of novel therapies for solid tumors and blood-related cancers designed to address significant unmet medical needs and improve treatment outcomes for patients. More information can be found at [www.seattlegenetics.com](http://www.seattlegenetics.com) and follow @SeattleGenetics on Twitter.

### **Forward-Looking Statements**

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the company's transition into a multi-product global oncology company, expectations regarding expansion of the commercial uses of ADCETRIS and advancing its late-stage oncology pipeline, including enfortumab vedotin, tisotumab vedotin and tucatinib and the company's other product candidates and those of its licensees and collaborators; as well as other statements that are not historical facts. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include that the company may be delayed in its planned clinical trial initiations, the enrollment in and conduct of its clinical trials, obtaining data from clinical trials, planned regulatory submissions, and regulatory approvals in each case for a variety of reasons including the difficulty and uncertainty of pharmaceutical product development, unexpected adverse events or regulatory discussions or actions, including with respect to special protocol assessment agreements defining trial endpoints and the inherent uncertainty associated with the regulatory approval process. The company may also be unable to expand ADCETRIS' labeled indications due to unexpected or delayed data from its ongoing phase 3 trials or regulatory action, including the risks that the company's supplemental BLA submissions may not be accepted for filing by, or ultimately approved by, the FDA in a timely manner or at all or with the requested label, and may be unable to complete the development of, and obtain regulatory approval for, its product candidates. Seattle Genetics may also not be able to integrate the acquired Cascadian Therapeutics business successfully or such integration may be more difficult, time-consuming or costly than expected. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption "Risk Factors" in the Company's Annual Report on Form 10K for the year ended December 31, 2017 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise except as required by applicable law.

###

### **CONTACTS:**

Investors:

Peggy Pinkston

(425) 527-4160

[ppinkston@seagen.com](mailto:ppinkston@seagen.com)

---

Media:

Tricia Larson

(425) 527-4180

[tlarson@seagen.com](mailto:tlarson@seagen.com)